Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients-Reference-Cited by-同舟云学术

Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients

Published:2017-04-08 Issue:9 Volume:17 Page:2372-2380
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Vanhove T.¹²^ORCID,Bouwsma H.³,Hilbrands L.⁴,Swen J. J.⁵,Spriet I.⁶⁷,Annaert P.⁸,Vanaudenaerde B.⁹,Verleden G.⁹,Vos R.⁹,Kuypers D. R. J.¹²

Affiliation:

1. Department of Microbiology and Immunology; KU Leuven-University of Leuven; Leuven Belgium

2. Department of Nephrology and Renal Transplantation; University Hospitals Leuven; Leuven Belgium

3. Department of Nephrology; Leiden University Medical Center; Leiden the Netherlands

4. Department of Internal Medicine: Nephrology and Kidney Transplantation; St Radboud University Medical Center; Nijmegen the Netherlands

5. Department of Clinical Pharmacy & Toxicology; Leiden University Medical Center; Leiden the Netherlands

6. Pharmacy Department; University Hospitals Leuven; Leuven Belgium

7. Department of Pharmaceutical and Pharmacological Sciences; Clinical Pharmacology and Pharmacotherapy; University of Leuven; Leuven Belgium

8. Drug Delivery and Disposition; Department of Pharmaceutical and Pharmacological Sciences; KU Leuven-University of Leuven; Leuven Belgium

9. Lung Transplant Unit; Division of Respiratory Disease; Department of Clinical and Experimental Medicine; KU Leuven-University of Leuven; Leuven Belgium

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajt.14232/fullpdf

Reference40 articles.

1. Invasive fungal infections in solid organ transplant recipients;Gavalda;Clin Microbiol Infect,2014

2. Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole;Moriyama;Curr Fungal Infect Rep,2015

3. EMA Vfend: EPAR http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000387/WC500049756.pdf

4. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes;Yanni;Drug Metab Dispos,2008

5. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers;Lee;J Clin Pharmacol,2012

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Individualized dosing parameters for tacrolimus in the presence of voriconazole: a real-world PopPK study;Frontiers in Pharmacology;2024-09-10

2. Guidance on Selecting Optimal Steady-State Tacrolimus Concentrations for Continuous IV Perfusion: Insights from Physiologically Based Pharmacokinetic Modeling;Pharmaceuticals;2024-08-08

3. Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study;2024-07-19

4. Removing the physician from the equation: Patient‐controlled, home‐based therapeutic drug self‐monitoring of tacrolimus;British Journal of Clinical Pharmacology;2024-06-03

5. Effect of Voriconazole on Tacrolimus Blood Concentration in Renal Transplant Recipients after Voriconazole Discontinuation;Journal of Clinical Pharmacy and Therapeutics;2024-03-13